Mohamed Wa'El Ahmed Hashad - 01 Jan 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role: Director
Signature: /s/ Rachelle Jacques, as Attorney-in-Fact for Mohamed Wa'el Hashad
Issuer symbol: AKTX
Transactions as of: 01 Jan 2024
Net transactions value: $0
Form type: 3
Filing time: 02 Jan 2024, 19:49:19 UTC
Previous filing: 13 Sep 2023
Next filing: 25 Jan 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AKTX	Stock Option (Right to Buy)							01 Jan 2024	Ordinary Shares, par value $0.0001 per share	5,000,000	$0.001700	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2024 Annual General Meeting.

Remarks:

See Exhibit 24.1 - Power of Attorney